Assuntos
Transtornos Plaquetários , Trombastenia , Transtornos Plaquetários/diagnóstico , Transtornos Plaquetários/genética , Transtornos Plaquetários/fisiopatologia , Transtornos Plaquetários/terapia , Plaquetas/metabolismo , Plaquetas/fisiopatologia , Triagem de Portadores Genéticos , Humanos , Glicoproteínas da Membrana de Plaquetas/metabolismo , Trombastenia/diagnóstico , Trombastenia/genética , Trombastenia/fisiopatologia , Trombastenia/terapiaAssuntos
Transtornos Plaquetários/fisiopatologia , Envelhecimento/fisiologia , Transtornos Plaquetários/etiologia , Plaquetas/efeitos dos fármacos , Plaquetas/fisiopatologia , Etanol/toxicidade , Circulação Extracorpórea , Doenças Hematológicas/complicações , Humanos , Hipertensão/complicações , Doenças Metabólicas/complicações , Glicoproteínas da Membrana de Plaquetas/imunologia , Diálise Renal/efeitos adversosRESUMO
Bernard-Soulier syndrome (BSS) is a rare autosomal bleeding disorder characterized clinically by prolonged skin bleeding time, normal clot retraction and thrombocytopenia with large and morphologically abnormal platelets, and biochemically by the absence of platelet membrane glycoproteins (GP) Ib, V and IX. GP Ib and GP IX exist in the platelet membrane as a heterodimer complex which acts as the major receptor mediating platelet adhesion to blood vessel subendothelium. Studies with BSS platelets have proved particularly rewarding in the investigation of the GP Ib-IX complex as a multifunctional receptor protein. The transmembrane complex contains binding domains for von Willebrand factor, thrombin, fibrin and quinine/quinidine drug-dependent antibodies as well as an attachment site on the cytoplasmic side of the membrane for a platelet cytoskeleton. In addition, the internal segment of the beta-chain of GP Ib contains a cyclic AMP-dependent protein kinase-associated phosphorylation site which appears to regulate platelet reactivity. Limited proteolytic cleavage of the complex, in particular the GP Ib alpha-chain, has allowed immunological and functional characterization of three distinct domains; a 45 kDa segment at the N-terminal end of the alpha-chain of GP Ib, which contains binding sites for von Willebrand factor and thrombin, a 90 kDa highly glycosylated region of GP Ib alpha and a membrane-associated region consisting of the remnant of GP Ib alpha disulphide-linked to GP Ib beta and non-covalently-complexed with GP IX. This membrane-associated region contains the antigenic epitope(s) for quinine/quinidine drug-dependent antibodies. It is highly probable that the future study of platelets from patients with the Bernard-Soulier syndrome will further clarify the role of the GP Ib-IX complex in platelet physiology.
Assuntos
Síndrome de Bernard-Soulier/fisiopatologia , Transtornos Plaquetários/fisiopatologia , Plaquetas/fisiologia , Transtornos Plaquetários/etiologia , Plaquetas/imunologia , Plaquetas/fisiopatologia , Membrana Celular/metabolismo , Fibrina/metabolismo , Humanos , Adesividade Plaquetária , Glicoproteínas da Membrana de Plaquetas/imunologia , Glicoproteínas da Membrana de Plaquetas/metabolismo , Receptores de Superfície Celular/metabolismo , Receptores de TrombinaAssuntos
Plaquetas/fisiopatologia , Doença das Coronárias/prevenção & controle , Trombose Coronária/prevenção & controle , Alho , Extratos Vegetais/uso terapêutico , Plantas Medicinais , Doença Aguda , Animais , Velocidade do Fluxo Sanguíneo , Constrição Patológica , Circulação Coronária , Trombose Coronária/patologia , Trombose Coronária/fisiopatologia , Vasos Coronários/patologia , Cães , Epinefrina/farmacologia , Feminino , MasculinoRESUMO
Adrenoceptor function is an important determinant of the physiological control of the circulation and of the response to drugs acting via the sympathetic nervous system and on the vasculature. There is little consistent evidence for an age-dependent change in alpha-adrenoceptor function though the response to various vasoconstrictor agents including alpha 1 agonists has been shown to change with ageing. These changes seem to reflect structural or functional factors and are not specific for receptor types. In the case of beta-adrenoceptor mediated responses there is evidence for both a decrease in response as well as age-related changes in the functioning of various components of the beta-adrenoceptor system, including receptor affinity, which is decreased. It may well be that decreased beta-adrenoceptor function with ageing contributes to altered cardiovascular control and to decreased efficacy of beta-adrenoceptor blocking drugs in elderly hypertensives.
Assuntos
Envelhecimento/fisiologia , Plaquetas/fisiopatologia , Sistema Cardiovascular/fisiopatologia , Receptores Adrenérgicos alfa/fisiologia , Receptores Adrenérgicos beta/fisiologia , Fatores Etários , Idoso , Sistema Cardiovascular/inervação , Humanos , Hipertensão/fisiopatologia , Músculo Liso Vascular/inervação , Sistema Nervoso Simpático/fisiopatologiaAssuntos
Doença das Coronárias/etiologia , Fumar/efeitos adversos , Arteriosclerose/etiologia , Arteriosclerose/fisiopatologia , Plaquetas/fisiopatologia , Circulação Coronária , Doença das Coronárias/mortalidade , Doença das Coronárias/fisiopatologia , Coração/fisiopatologia , Humanos , Leucócitos/fisiologia , Sistema Vasomotor/fisiopatologiaRESUMO
10 consecutive patients fulfilled the diagnostic criteria for lupus anticoagulant. 4 had concomitant systemic lupus erythematosus, 1 Waldenstrom's disease and 5 had no apparent underlying disease. Only the case with Waldenstrom's disease presented a bleeding tendency, with bleeding time greater than 20 min; the others had a history of thrombotic complications. A defect of platelet aggregation induced by ADP, epinephrine, collagen and arachidonic acid was documented in the Waldenstrom's disease case whose lupus anticoagulant was an IgM. In the others, lupus anticoagulant, identified as IgG immunoglobulins, produced no aggregation abnormalities. However, beta-thromboglobulin levels in platelets, plasma and urine were consistent with a pattern of platelet activation in all cases. IgG immunoglobulins separated from sera of 6 patients showed lupus anticoagulant activity, with no effects on platelet aggregation of normal platelet-rich plasma, but they induced secretion of beta-thromboglobulin from normal platelets.
Assuntos
Transtornos da Coagulação Sanguínea/fisiopatologia , Fatores de Coagulação Sanguínea/imunologia , Plaquetas/fisiopatologia , Adulto , Fatores de Coagulação Sanguínea/análise , Plaquetas/efeitos dos fármacos , Feminino , Humanos , Imunoglobulina G/análise , Imunoglobulina M/análise , Inibidor de Coagulação do Lúpus , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária , Contagem de Plaquetas , Serotonina/análise , beta-Tromboglobulina/análiseRESUMO
Platelet function tests including platelet aggregation, PF3, bleeding time and clot retraction were studied in 48 malarial patients. The suppression of platelet aggregation was demonstrated in both P. vivax and P. falciparum infection. However, this abnormality was more prominent in malarial patients who had systemic complications and bleeding. The recovery of the impaired platelet aggregation was observed at period of 7 and 14 days after parasitemia in malarial patients without and with systemic complications. The correlation between the suppression of platelet aggregation and thrombocytopenia was observed. From this study, bleeding in malaria are operated by two mechanisms: thrombocytopenia and severely depressed platelet aggregation.
Assuntos
Coagulação Sanguínea , Plaquetas/fisiopatologia , Malária/sangue , Adulto , Animais , Tempo de Sangramento , Retração do Coágulo , Feminino , Hemorragia/sangue , Hemorragia/complicações , Humanos , Malária/complicações , Malária/parasitologia , Masculino , Plasmodium falciparum , Plasmodium vivax , Agregação Plaquetária , Contagem de PlaquetasRESUMO
Blood platelet activity and levels of proteinase inhibitors and proteolytic components were assessed in patients with progressive angina of effort, spontaneous angina and acute myocardial infarction. alpha 1-antitrypsin and alpha 2-macroglobulin were shown to be involved in fibrinolysis regulation and kininogenesis. In acute myocardial infarction, there was a close inverse correlation between platelet release and blood kallikrein levels.
Assuntos
Plaquetas/fisiopatologia , Doença das Coronárias/sangue , Inibidores de Proteases/sangue , Doença Aguda , Adulto , Idoso , Idoso de 80 Anos ou mais , Antitrombina III/fisiologia , Humanos , Calicreínas/sangue , Pessoa de Meia-Idade , alfa 1-Antitripsina/fisiologia , alfa-Macroglobulinas/fisiologiaAssuntos
Infarto do Miocárdio/fisiopatologia , Angina Pectoris/fisiopatologia , Angioplastia com Balão , Plaquetas/metabolismo , Plaquetas/fisiopatologia , Ponte de Artéria Coronária , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/metabolismo , Doença das Coronárias/fisiopatologia , Doença das Coronárias/cirurgia , Trombose Coronária/metabolismo , Eletrofisiologia , Humanos , Contração Miocárdica , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/cirurgiaAssuntos
Angiopatias Diabéticas/etiologia , Terapêutica/tendências , Antioxidantes/farmacologia , Membrana Basal/citologia , Membrana Basal/fisiopatologia , Plaquetas/citologia , Plaquetas/fisiopatologia , Vasos Sanguíneos/citologia , Vasos Sanguíneos/fisiopatologia , Capilares/citologia , Capilares/fisiopatologia , Angiopatias Diabéticas/genética , Angiopatias Diabéticas/terapia , Endotélio Vascular/citologia , Endotélio Vascular/fisiopatologia , Imunofluorescência , Radicais Livres , Predisposição Genética para Doença , Glicosilação , Humanos , Prostaglandinas/biossíntese , Prostaglandinas/fisiologiaRESUMO
Synthetic stable analogues of thromboxane A2 (TXA2), cyclic endoperoxides (PGH2) and prostacyclin (PGI2) opened up new opportunities for investigating the mechanisms of action of these compounds. They proved to be useful pharmacological probes for characterizing PGI2 and TXA2/PGH2 receptors. Over the past few years, new synthetic antagonists with high specificity allowed the modulation of biological responses to endogenous eicosanoids. These compounds will, therefore, considerably promote our understanding of the biological function and significance of arachidonate metabolites. The present review summarizes current concepts that have arisen concerning platelet and vascular PGI2 and TXA2/PGH2 receptors, their transmembrane signal transduction, as well as their possible implications in the pathophysiology of cardiovascular disease.
Assuntos
Plaquetas/fisiologia , Epoprostenol/fisiologia , Músculo Liso Vascular/fisiologia , Receptores de Prostaglandina/fisiologia , Tromboxanos/fisiologia , Adenilil Ciclases/metabolismo , Plaquetas/fisiopatologia , Cálcio/metabolismo , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/fisiopatologia , AMP Cíclico/fisiologia , Humanos , Hidrólise , Canais Iônicos/metabolismo , Fosfatidilinositóis/metabolismo , Receptores de Epoprostenol , Receptores de Prostaglandina/antagonistas & inibidores , Receptores de Tromboxanos , Tromboxanos/antagonistas & inibidoresRESUMO
The role of blood platelets in producing early intimal changes in cerebral arteries following subarachnoid hemorrhage (SAH) was examined by using 18 cats. Experimental SAH was produced by a rupture of the proximal portion of the right middle cerebral artery. Following SAH, the scanning electron microscope revealed that structural alterations in the intimal layer of major cerebral arteries occurred as early as 2 hours and became more severe by 48 hours. Vascular alterations, which were predominantly detected in the ruptured vessel, consisted of endothelial cell corrugation, detachment, crater formation, intimal adhesion of platelets and red blood cells, intimal thrombi, and reendothelialization. When cats were pretreated prior to SAH with an anti-platelet-aggregating agent, OKY-1581, the intimal blood elements and thrombi were clearly reduced, and reendothelialization was not observed. However, endothelial cell changes in the OKY-1581-treated group were very similar to those occurring in the nontreated group. While these results suggest that bioactive substances contained within blood platelets, such as growth factors, serotonin, and norepinephrine, have little effect on producing endothelial cell injury, platelets may be important in the initiation of reendothelialization following vessel injury.
Assuntos
Plaquetas/fisiopatologia , Artérias Cerebrais/patologia , Hemorragia Subaracnóidea/patologia , Animais , Plaquetas/patologia , Adesão Celular , Artérias Cerebrais/ultraestrutura , Eritrócitos/patologia , Eritrócitos/fisiologia , Metacrilatos/farmacologia , Microscopia Eletrônica de Varredura , Hemorragia Subaracnóidea/fisiopatologiaRESUMO
Earlier results indicated a diminished labelling efficiency and recovery negatively linked to actual cholesterol and lipoprotein values in hyperlipoproteinemics. This study was designed to examine whether other alternative tracers exhibit similar results and to study the influence on platelet viability in the presence or absence of PGI2. We demonstrate that no substantial difference occurs between the four tracers concerning labelling efficiency and recovery in normo- and hypercholesterolemics. Cholesterol severely affects the labelling parameters for all the tracers to a comparable extent. The absolute platelet function varies considerably, however, the percent changes in normo- and hypercholesterolemics seen before and after the labelling procedure do not differ significantly. PGI2 improves recovery in general, however, without affecting labelling efficiency or in vitro viability testing. As prolonged incubation further increases labelling efficiency, the presence and extent of hyperlipoproteinemia should be known in order to avoid poor labeling and viability and subsequently poor clinical results.
Assuntos
Plaquetas/fisiopatologia , Hipercolesterolemia/sangue , Radioisótopos de Índio , Marcação por Isótopo , Adulto , Idoso , Movimento Celular , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Compostos Organometálicos , Oxiquinolina/análogos & derivados , Agregação Plaquetária , Piridinas , Tionas , TropolonaRESUMO
Blood platelets contain several growth factors and inhibitors. The better known among them are named platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF beta), active as modulators of growth of normal mesenchymal and epithelial cells. Cancer cell growth in vitro seems to be independent of the effects of exogenous peptides, but dependent on the cell ability to release autocrine growth factors, similar to PDGF or TGF beta. In addition, platelet-associated growth factors and inhibitors, which are able to induce a fibrotic response in connective tissue cells, might also play a role to modulate the desmoplastic reaction surrounding the tumor.
Assuntos
Plaquetas/fisiopatologia , Metástase Neoplásica/fisiopatologia , Neoplasias/fisiopatologia , Fator de Crescimento Derivado de Plaquetas/fisiologia , Movimento Celular/efeitos dos fármacos , Transformação Celular Neoplásica/fisiopatologia , Humanos , Peptídeos/farmacologia , Fatores de Crescimento TransformadoresRESUMO
Platelets are thought to be involved in the development of blood borne metastasis. Ultrastructural and experimental studies demonstrate that association between tumor cells and platelets with subsequent activation of the coagulation cascade takes place in malignancy. Several hypotheses have been proposed to explain the mechanisms by which tumor cells activate platelets including generation of thrombin, ADP release and involvement of arachidonate metabolism. Perfusion studies with human homologous systems showed that intact tumor cells and tumor cell microvesicles were able to induce platelet thrombogenicity under defined flow conditions. The presence of divalent cations and plasma factors was necessary for the cancer cells to exert their activating capacity. These results suggest a role for platelets in the development of secondary metastasis as well as in the thrombotic events of malignancy.
Assuntos
Plaquetas/fisiopatologia , Metástase Neoplásica/sangue , Neoplasias Experimentais/fisiopatologia , Agregação Plaquetária , Difosfato de Adenosina/metabolismo , Animais , Plaquetas/patologia , Comunicação Celular , Humanos , Neoplasias Experimentais/patologiaRESUMO
The ability of tumor cells to initiate coagulation and subsequent platelet aggregation is believed to facilitate the metastatic process. The mechanism by which tumor cells initiate thrombotic alterations is unclear. We have purified a plasma membrane protein platelet aggregating activity/procoagulant activity (PAA/PCA) from several rodent tumors which initiates the coagulation of homologous plasma and aggregation of homologous platelets by a mechanism independent of factor VII. This protein does not possess any proteinase activity; however, its activity is dependent upon the presence of factor X. In addition, PAA/PCA requires reconstitution with phospholipid for expression of activity. These results suggest that tumor cells express a unique protein which possesses procoagulant activity resulting in thrombin generation. Thrombin is responsible for subsequent tumor-cell-induced platelet aggregation.
Assuntos
Coagulação Sanguínea , Metástase Neoplásica/etiologia , Neoplasias Experimentais/patologia , Agregação Plaquetária , Aminoácidos/análise , Animais , Plaquetas/fisiopatologia , Humanos , Metástase Neoplásica/fisiopatologia , Neoplasias Experimentais/sangue , Trombina/antagonistas & inibidoresRESUMO
Platelet function was studied during coronary angiography of patients complaining of chest pain. The following changes occurred 5 min after injecting 100 IU.kg-1 body weight of a conventional high molecular weight heparin: (a) a significant fall in platelet count; (b) a significant enhancement of platelet aggregation in platelet rich plasma (turbidometric technique) and in whole blood (platelet aggregation technique); and (c) significantly enhanced release of platelet thromboxane A2, a vasoconstrictor. These changes tended to reverse towards baseline values 5 min after injecting a contrast medium (Conray 420), which was found to inhibit platelet aggregation. Thus heparinisation with a high molecular weight heparin seems to cause pronounced activation of platelets in patients undergoing coronary angiography, and this may contribute to the pathogenesis of cardiac ischaemia that may occur during this procedure. Since coronary artery bypass surgery in similar patients involves the use of heparin at much higher doses without the concomitant use of an antiaggregatory contrast medium, it is possible that platelet hyperaggregability may contribute to the well documented ischaemic brain injury associated with this form of surgery. Furthermore, the use of high molecular weight heparin after successful coronary angioplasty or thrombosis may influence the incidence of reocclusion. These findings therefore suggest that low molecular weight heparinoids should be evaluated in these situations since these anticoagulants are only weak activators of platelet aggregation.